Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

A 75-year-old man with non-small cell lung cancer shows radiologic enlargement after neoadjuvant therapy; however, ...

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

In a Nov. 21 note, he maintained a “Speculative Buy” rating and C$5.25 (US$4.00) target.

Organoid-on-chip technology merges patient-derived organoids with microfluidic engineering to recreate human physiology and ...

"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by ...

The firm plans to submit results from the Phase III OptiTROP-Lung05 trial to regulators in China, seeking approval for sac-TMT and Keytruda in PD-L1-positive patients.

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership; Company is in advanced stages to finalize a strat ...

Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM ESTCompany ParticipantsJan van de Winkel - Co-Founder, ...